Free Trial

Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

CompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's Volume
Lifevantage Corporation stock logo
LFVN
Lifevantage
$12.58
+0.2%
$12.82
$7.09
$27.38
$157.98M0.45134,697 shs64,103 shs
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$7.65
$7.06
$3.85
$8.98
$614.79M1.25665,612 shs513,206 shs
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$2.22
-5.1%
$2.40
$1.66
$9.95
$595.90M0.281.51 million shs1.18 million shs
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$8.35
-2.2%
$8.33
$2.21
$19.71
$596.21M0.45911,990 shs501,927 shs
Options Trading Made Easy - Download Now Cover

Learn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.

Get This Free Report

Compare Price Performance

Company1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year Performance
Lifevantage Corporation stock logo
LFVN
Lifevantage
+0.24%-8.24%-6.12%+5.63%+53.79%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
0.00%-8.60%+10.55%+5.52%+46.27%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-5.13%-17.47%-16.23%+7.25%-77.18%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-2.22%-13.29%-6.29%+202.54%-29.36%
CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & Valuation
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.8043 of 5 stars
3.50.01.72.71.12.51.3
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
4.135 of 5 stars
3.53.00.04.81.12.50.6
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
3.7585 of 5 stars
3.11.00.04.42.70.81.3
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
2.6359 of 5 stars
3.52.00.00.00.05.00.6
CompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current Price
Lifevantage Corporation stock logo
LFVN
Lifevantage
3.00
Buy$30.50142.45% Upside
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
3.00
Buy$24.00213.73% Upside
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.25
Hold$6.64199.05% Upside
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
3.00
Buy$17.50109.58% Upside

Current Analyst Ratings Breakdown

Latest LFVN, MRVI, MGTX, and PHAT Analyst Ratings

DateCompanyBrokerageActionRatingPrice TargetDetails
6/9/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Boost Price TargetBuy ➝ Buy$12.00 ➝ $17.00
6/9/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$20.00
6/6/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Needham & Company LLC
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingBuy ➝ Buy$28.00
5/14/2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
Chardan Capital
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$38.00 ➝ $35.00
5/13/2025
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
Craig Hallum
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$12.00 ➝ $10.00
5/13/2025
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
Robert W. Baird
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$3.00 ➝ $2.00
5/2/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetNeutral ➝ Neutral$10.00 ➝ $5.00
5/2/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
Guggenheim
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$18.00 ➝ $12.00
5/2/2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Lower Price TargetBuy ➝ Buy$28.00 ➝ $20.00
(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)
CompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/Book
Lifevantage Corporation stock logo
LFVN
Lifevantage
$200.16M0.79$0.88 per share14.23$2.05 per share6.14
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
$33.28M18.47N/AN/A$0.87 per share8.79
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
$259.18M2.18$0.59 per share3.79$2.28 per share0.97
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
$55.25M10.55N/AN/A($3.71) per share-2.25
CompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings Date
Lifevantage Corporation stock logo
LFVN
Lifevantage
$2.94M$0.6918.23N/A4.12%34.67%15.24%8/27/2025 (Estimated)
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$147.79M-$2.32N/A20.13N/A-484.90%-241.05%-62.93%8/11/2025 (Estimated)
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$144.85M-$1.14N/AN/AN/A-67.14%-12.91%-6.87%8/11/2025 (Estimated)
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-$334.33M-$5.24N/AN/AN/A-422.42%N/A-90.11%8/7/2025 (Estimated)

Latest LFVN, MRVI, MGTX, and PHAT Earnings

DateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails
8/27/2025Q4 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.17N/AN/AN/A$57.93 millionN/A
8/11/2025Q2 2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.52N/AN/AN/A$8.00 millionN/A
8/11/2025Q2 2025
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$0.06N/AN/AN/A$47.46 millionN/A
8/7/2025Q2 2025
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
-$0.76N/AN/AN/A$35.58 millionN/A
5/13/2025Q1 2025
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
-$0.38-$0.51-$0.13-$0.51$4.44 million$1.93 million
5/12/2025Q1 2025
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
-$0.07-$0.08-$0.01-$0.21$44.01 million$46.85 million
5/6/2025Q3 2025
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.16$0.26+$0.10$0.26$60.99 million$58.44 million
CompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive Growth
Lifevantage Corporation stock logo
LFVN
Lifevantage
$0.181.43%N/A26.09%3 Years
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
N/AN/AN/AN/AN/A
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
N/AN/AN/AN/AN/A
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/AN/AN/AN/AN/A
CompanyDebt-to-Equity RatioCurrent RatioQuick Ratio
Lifevantage Corporation stock logo
LFVN
Lifevantage
N/A
1.66
0.98
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
2.34
1.53
1.51
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
0.60
5.96
5.17
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
N/A
3.58
3.54

Institutional Ownership

CompanyInstitutional Ownership
Lifevantage Corporation stock logo
LFVN
Lifevantage
35.32%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
67.48%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
50.25%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
99.01%

Insider Ownership

CompanyInsider Ownership
Lifevantage Corporation stock logo
LFVN
Lifevantage
20.65%
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
7.50%
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
2.11%
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
23.00%
CompanyEmployeesShares OutstandingFree FloatOptionable
Lifevantage Corporation stock logo
LFVN
Lifevantage
26012.59 million9.99 millionOptionable
MeiraGTx Holdings PLC stock logo
MGTX
MeiraGTx
30080.36 million74.34 millionOptionable
Maravai LifeSciences Holdings, Inc. stock logo
MRVI
Maravai LifeSciences
610254.66 million249.29 millionOptionable
Phathom Pharmaceuticals, Inc. stock logo
PHAT
Phathom Pharmaceuticals
11069.81 million53.76 millionOptionable

Recent News About These Companies

Phathom Pharmaceuticals, Inc. (PHAT) - Yahoo Finance
Phathom Pharmaceuticals Appoints Cook as Chief Legal Officer

New MarketBeat Followers Over Time

Media Sentiment Over Time

Lifevantage stock logo

Lifevantage NASDAQ:LFVN

$12.58 +0.03 (+0.24%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$12.57 -0.01 (-0.08%)
As of 08/1/2025 05:46 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

LifeVantage Corporation engages in the identification, research, development, formulation, and sale of advanced nutrigenomic activators, dietary supplements, nootropics, pre- and pro-biotics, weight management, skin and hair care, bath and body, and targeted relief products. It offers Protandim, a dietary supplement; LifeVantage Omega+, a dietary supplement that combines DHA and EPA Omega-3 fatty acids, Omega-7 fatty acids, and vitamin D3; LifeVantage ProBio, a dietary supplement to support gut health; PhysIQ, a weight management system; LifeVantage IC Bright, a supplement to support eye and brain health, reduce eye fatigue and strain, supports cognitive functions, and support normal sleep patterns; Petandim for Dogs, a supplement to combat oxidative stress in dogs; and Axio, a nootropic energy drink mix. The company also provides anti-aging skin care products, including liquid collagen, facial cleansers, perfecting lotions, eye serums, anti-aging creams, hand creams, beauty serum, as well as hair care products, such as invigorating shampoos, nourishing conditioners, and scalp serums under the LifeVantage TrueScience brand name. In addition, it offers bath and body, and targeted relief products, such as body lotion, body wash, body butter, deodorant, soothing balm, and body rub under the TrueScience brand name. It sells its products through its website and network of independent distributors in the United States, Mexico, Japan, Australia, Hong Kong, Canada, Thailand, the United Kingdom, the Netherlands, Germany, Taiwan, Austria, Spain, Ireland, Belgium, New Zealand, Singapore, and the Philippines. The company was founded in 2003 and is headquartered in Lehi, Utah.

MeiraGTx stock logo

MeiraGTx NASDAQ:MGTX

$7.65 0.00 (0.00%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$7.65 0.00 (0.00%)
As of 08/1/2025 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

MeiraGTx Holdings plc, a clinical stage gene therapy company, focusing on developing treatments for patients with serious diseases. The company develops various therapies for ocular diseases, including inherited retinal diseases and large degenerative ocular diseases, neurodegenerative diseases, and xerostomia. Its programs in clinical development include Phase I/II clinical stage programs in achromatopsia, X-linked retinitis pigmentosa, and RPE65-deficiency; Phase I clinical trials for radiation-induced xerostomia; and Parkinson's program that has completed a Phase II trial. It has a research collaboration agreement with Janssen Pharmaceuticals, Inc. for the research, development, and commercialization of gene therapies for the treatment of inherited retinal disease. The company was incorporated in 2015 and is based in New York, New York.

Maravai LifeSciences stock logo

Maravai LifeSciences NASDAQ:MRVI

$2.22 -0.12 (-5.13%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$2.22 +0.00 (+0.23%)
As of 08/1/2025 07:19 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Maravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.

Phathom Pharmaceuticals stock logo

Phathom Pharmaceuticals NASDAQ:PHAT

$8.35 -0.19 (-2.22%)
Closing price 08/1/2025 04:00 PM Eastern
Extended Trading
$8.40 +0.05 (+0.59%)
As of 08/1/2025 06:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Phathom Pharmaceuticals, Inc., biopharmaceutical company, focuses on developing and commercializing treatments for gastrointestinal diseases. The company has the rights in the United States, Europe, and Canada for an investigational potassium-competitive acid blocker (P-CAB) that blocks acid secretion in the stomach. It is also developing vonoprazan for the treatment of erosive gastroesophageal reflux disease; and in combination with antibiotics for the treatment of Helicobacter pylori infection. The company was incorporated in 2018 and is headquartered in Florham Park, New Jersey.